TipRanks on MSN
Daiichi Sankyo’s Promising Study on R-DXd for Resistant Ovarian Cancer: A Market Game-Changer?
Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
Junior High School DxD begins with its first volume titled “The Transfer Student Is a Samurai Girl” that is now hitting shelves across Japan. Introducing fans to a new main protagonist named Zetta ...
TipRanks on MSN
Daiichi Sankyo’s Promising Study on Ifinatamab Deruxtecan: A Potential Game-Changer in Oncology
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Daiichi Sankyo Company (DSKYF) is currently conducting a ...
AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to differentiate the antibody-drug conjugate (ADC) ...
When Merck & Co. and Daiichi Sankyo last year received an FDA complete response letter for their HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan, the companies hoped to address ...
New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
Patients with advanced squamous or nonsquamous NSCLC without a common EGFR-activating mutation whose disease had progressed on previous therapies including platinum-based chemotherapy, immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback